TechnipFMC plc Ordinary Share vs Regeneron Pharmaceuticals Inc — how do they compare? TechnipFMC plc Ordinary Share trades at $69.63 (market cap $27.31B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.8× TechnipFMC plc Ordinary Share's market cap, and Regeneron Pharmaceuticals Inc pays the higher dividend (0.51%). Which is the better fit depends on your goals — on Pluang, investors hold TechnipFMC plc Ordinary Share for 0 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| FTI | REGN | |
|---|---|---|
Market Cap | $27.31B | $76.14B |
Volume | 2,496,410 | 500,239 |
Sector | Energy | Health |
52-Week High | $80.08 | $852.03 |
52-Week Low | $35.57 | $557.73 |
Typical Hold Time | 0 Days | 107 Days |
Enterprise Value | $27.56B | $70.85B |
Dividend Yield | 0.29% | 0.51% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
TechnipFMC is an energy technology company providing subsea systems, surface technologies, and related services across the life of oil and gas fields. Its offerings include equipment, controls, installation support, and digital tools for offshore and onshore projects.
Read more on FTI →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →